Nantong Jinghua In-licenses Two Cancer mAbs for $50 Million

Nantong Jinghua Pharma struck a $50 million deal to acquire China rights for two anti-cancer monoclonal antibodies from Kadmon Corporation of New York. The molecules, both of which are in preclinical development, are fully human anti-VEGFR2 and anti-PD-L1 mAbs. Jinghua also in-licensed rights to Kadmon's mAb discovery technology. Jinghua made a $10 million equity investment in Kadmon and agreed to a package of $40 million in milestones and a 10% royalty on sales. More details.... Stock Symbol: (SHZ: 002349) Share this with colleagues: // //